Treatment of infertility in women with polycystic ovary syndrome using assisted reproductive technology

Cover Page

Abstract


The article recent data concerning the pathogenesis, diagnostic criteria and hormonal disorders in the polycystic ovary syndrome are presented. A sequential step-by-step treatment of this disease is also described. Pаrticulаr аttention is pаid to the treаtment of infertility in women with PCOS using аssisted reproductive technology.


Roza M. Danielyan

Author for correspondence.
roza.danielyan.10@mail.ru
St Petersburg State University
Russian Federation, Saint Petersburg

PhD student of the Department of Obstetrics, Gynecology and Reproduction, Medical Faculty

Alexander M. Gzgzyan

iagmail@ott.ru
St Petersburg State University
Russian Federation, Saint Petersburg

MD, Professor of the Department of Obstetrics, Gynecology and Reproduction, Medical Faculty

  • Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370:685-97. doi: 10.1016/S0140-6736(07)61345-2.
  • Fauser BC, Tarlatzic BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38. doi: 10.1016/j.fertnstert.2011.09.024.
  • Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype аnd cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Reproductive endocrinology. 2012;27(10):3067-73. doi: 10.1093/humrep/des232.
  • Azziz R, Carmina E, Devvailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88. doi: 10.1016/j.fertnstert.2008.06.035.
  • Назаренко Т.А. Синдром поликистозных яичников: современные подходы к диагностике и лечению бесплодия. – М.: МЕДэкспресс-информ, 2005. – 208 с. [Nazarenko TA. Sindrom polikistoznykh yaichnikov: sovremennye podkhody k diagnostike i lecheniyu besplodiya. Moscow: MEDekspress-inform; 2005. 208 p. (In Russ.)]
  • Манухин И.Б., Геворкян М.А., Кушлинский Н.Е. Синдром поликистозных яичников. – М.: МИА, 2004. – 189 с. [Manukhin IB, Gevorkyan MA, Kushlinskii NE. Sindrom polikistoznykh yaichnikov. Moskow: MIA; 2004. 189 p. (In Russ.)]
  • Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016Aug11;2:16057. doi: 10.1038/nrdp.2016.57.
  • Rotterdam E. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):19-25.
  • Хачкурузов Я.К. К вопросу о мелкокистозном перерождении и фолликулярных кистах яичника // Журнал акушерства и женских болезней. – 1995. – Т. 29. – № 4. – С. 373–390. [Khachkuruzov YK. K voprosu o melkokistoznom pererozhdenii i follikulyarnykh kistakh yaichnika. Journal of Obstetrics and Women’s Diseases.1995;29(4):373-90. (In Russ.)]
  • Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91. doi: 0.1016/S0002-9378(15)30642-6.
  • Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014;127(10):912-9. doi: 10.1016/j.amjmed.2014.04.017.
  • Dumitrescu R, Mehedintu C, Briceag I, et al. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life. 2015;8(2):142-5.
  • Madnani N, Khan K, Chauhan P, et al. Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 2013;79(3):310-21. doi: 10.4103/0378-6323.110759.
  • Дедов И.И., Мельниченко Г.А., ред. Синдром поликистозных яичников: руководство для врачей. – М.: МИА, 2007. – 368 с. [Dedov II, Mel’nichenko GA, eds. Sindrom polikistoznykh yaichnikov: rukovodstvo dlya vrachei. Moscow: MIA; 2007. 368 p. (In Russ.)]
  • Yen SS. The polycystic ovary syndrome. Clin Endocrinol. 1980;12:177-208. doi: 10.1111/j.1365-2265.1980.tb02132.x.
  • Homburg R. Polycystic ovary syndrome. Obstet Gynecol. 2008;22:261-24. doi: 10.1016/j.bpobgyn.2007.07.009.
  • Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Reviews. 1997;18(6):774-800. doi: 10.1210/edrv.18.6.0318.
  • Tucci S, Futterweit W, Concepsion ES, et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab. 2001;86:446-9. doi: 10.1210/jcem.86.1.7274.
  • Rojas J, Chaves M, Olivar L, et al. Polycystic Ovary Syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J of Reprod Med. 2014;2014:719050. doi: 10.1155/2014/719050. Epub 2014 Jan 28.
  • Amini M, Horri N, Farmani M, et al. Prevalence of polycystic ovary syndrome in peproductive-aged women with type 2 diabetes. Gynecol Endocrinol. 2008;24:423-31. doi: 10.1080/09513590802306143.
  • Poretsky L, Cataldo N, Rosewaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20:532-82. doi: 10.1210/edrv.20.4.0374.
  • Савельевa Г.М., ред. Гинекология. Национальное руководство: краткое издание. – М.: ГЭОТАР-Медиа, 2015. – 704 с. [Savel’eva GM. ed. Ginekologiya. Natsional’noe rukovodstvo: kratkoe izdanie. Moscow: GEOTAR-Media; 2015. 704 p. (In Russ.)]
  • Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. – 3-е изд. – М.: МЕДпресс-информ, 2015. – 512 с. [Serov VN, Prilepskaya VN, Ovsyannikova TV. Ginekologicheskaya endokrinologiya. Moscow: MEDpress-inform; 2015. 512 p. (In Russ.)]
  • Fallat ME, Siow Y, Cook C, et al. Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril. 1997;67:962-5. doi: 10.1016/S0015-0282(97)81417-3.
  • Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicle arrest. J Clin Endocrinol Metab. 2003;88:5957-62. doi: 10.1210/jc.2003-030727.
  • Carlsen SM, Vanky E, Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod. 2009;24:1732-8. doi: 10.1093/humrep/dep074.
  • Das M, Gillott DJ, Saridogan EO. Djahanbakhch. Anti-Müllerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod. 2008;23:2122-6. doi: 10.1093/humrep/den185.
  • Goodman NF, Cobin RH, Futterweit W, et al.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Ndocrinology, And Androgen Excess and Pcos Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome. Pt 1. Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.
  • Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):76-105. doi: 10.1093/humupd/dmt038.
  • Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41-7. doi: 10.5812/ijem.4158.
  • Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4): P1-29. doi: 10.1530/EJE-14-0253.
  • Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014;102(2):460-8. doi: 10.1016/j.fertnstert.2014.04.046.
  • Prelevic GM. Symptomatic treatment of acne and hirsutism. In: Homberg R., ed. Polycystic ovary syndrome. London; 2001. P. 110-1.
  • Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin Endocrinol Metab. 2015;100(3):911-9. doi: 10.1210/jc.2014-3886.
  • Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-22. doi: 10.1016/j.fertnstert.2007.09.041.
  • Dewailly D, et al. Polycystic ovary syndrome. Ann Endocrinol. 2010;71:8-13. doi: 10.1016/j.ando.2009.12.003.
  • Краснопольская К.В., Назаренко Т.А. Клинические аспекты лечения бесплодия в браке. Диагностика и терапевтические программы: руководство. – М.: ГЭОТАР-Медиа, 2014. [Krasnopol’skaya KV, Nazarenko TA. Klinicheskie aspekty lecheniya besplodiya v brake. Diagnostika i terapevticheskie programmy: rukovodstvo. Moscow: GEOTAR-Media; 2014. (In Russ.)]
  • Berger JJ, Bates GW. Optimal management of subfertility in polycystic ovary syndrome. Int J Womens Health. 2014;6:613-21. doi: 10.2147/IJWH.S48527.
  • Weiss NS, Nahuis M, Bayram N, et al. Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst Rev. 2015;9. doi: 10.1002/14651858.CD010290.pub2.
  • Amer SA, Li TC, Cooke ID. A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy. Hum Reprod. 2003;18:1693-8. doi: 10.1093/humrep/deg307.
  • Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012;6. doi: 10.1002/14651858.CD001122.pub4.
  • Калугина А.С., Бобров К.Ю. Синдром поликистозных яичников: современные представления и роль в проблеме бесплодия // Проблемы репродукции. – 2015. – № 2. – C. 31–35. [Kalugina AS, Bobrov KYu. Polycyctic ovary syndrome: modern view and it’s role in infertility. Problemy reproduktsii. 2015;(2):31-5. (In Russ.)]. doi: 10.17116/repro201521231-35.
  • Жорданидзе Д.О., Назаренко Т.А., Муллабаева С.М. Изменение концентраций антимюллерова гормона при стимуляции яичников гонадотропинами / Материалы IV международного конгресса по репродуктивной медицине. – M., 2011. – C. 319. [Zhordanidze DO, Nazarenko TA, Mullabaeva SM. Izmenenie kontsentratsii antimyullerova gormona pri stimulyatsii yaichnikov gonadotropinami. (Conference proceedings) Materialy IV mezhdunarodnogo kongressa po reproduktivnoi meditsine. Moskow; 2011. P. 319. (In Russ.)]
  • Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123-9. doi: 10.1093/humrep/der297.
  • Köninger A, Sauter L, Edimiris P, et al. Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome. Hum Reprod. 2014;29(3):518-24. doi: 10.1093/humrep/det468.
  • Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;(11): CD006105. doi: 10.1002/14651858.CD006105.pub3.
  • Cheng J, Lv J, Li CY, et al. Clinical outcomes of ovulation induction with metformin, clomiphene citrate and human menopausal gonadotrophin in polycystic ovary syndrome. J Int Med Res. 2010;38(4):1250-8. doi: 10.1177/147323001003800406.
  • Christianson MS, Wu H, Zhao Y, et al. Metformin use in patients undergoing in vitro fertilization treatment: results of worldwide web-based survey. J Assist Reprod Genet. 2015;32(3):401-6. doi: 10.1007/s10815-014-0414-x.
  • Orvieto R, Nahum R, Meltcer S, et al. Ovarium stimulation in polycystic ovary syndrome patients: the role of body mass index. Reprod Biomed Online. 2009;18:333-6. doi: 10.1016/S1472-6483(10)60090-9.
  • Frydman R. In vitro Fertilization: innovative research to give life. 2010;26(12):1007-8. doi: 10.1051/medsci/201026121007.
  • Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod. 2010Mar;25(3):683-9. doi: 10.1093/humrep/dep436.
  • Kurzawa R, Ciepiela P, Baczkowski T, et al. Comparison of embryological and clinical outcome in GnRG antagonist vs. GnRG agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study. J Assist Reprod Genet. 2008;25:356-74. doi: 10.1007/s10815-008-9249-7.
  • Кулаков В.И., Калинина Е.А., Корнеева И.Е., и др. Синдром гиперстимуляции в программе ЭКО и ПЭ // Экстракорпоральное оплодотворение и его новые направления в лечении женского бесплодия. – М.: МИА, 2000. – С. 410–469. [Kulakov VI, Kalinina EA, Korneeva IE, et al. Sindrom giperstimulyatsii v programme EKO i PE. In: Ekstrakorporal’noe oplodotvorenie i ego novye napravleniya v lechenii zhenskogo besplodiya. Moscow: MIA; 2000. P. 410-69. (In Russ.)]
  • Corbett S, Shmorgun D, Claman P. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can. 2014;36(11):1024-36. doi: 10.1016/S1701-2163(15)30417-5.
  • Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;(10): CD008046. doi: 10.1002/14651858.CD008046.pub4.
  • Lin YH, Huang MZ, Hwang JL, et al. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels: a retrospective study. J Assist Reprod Genet. 2013;30(6):753-9. doi: 10.1007/s10815-013-9997-x.

Views

Abstract - 144

PDF (Russian) - 68


Copyright (c) 2017 ECO-vector LLC

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.